Brought to you by 
Agios nets $516mm through public offering
24 Jan 2018
Executive Summary
Agios Pharmaceuticals Inc. (therapies for cancer and rare genetic diseases) netted $516mm through a public offering of 8.1mm common shares (including the overallotment) at $67. Proceeds will support the company's pipeline activities, including late-stage development, approval, and commercial launch of ivosidenib for acute myeloid leukemia and solid tumors, and planned trials with AG348 for PK deficiency and thalassemia.
Deal Industry
- Pharmaceuticals
-
Pharmaceuticals
- Vaccines
-
Biotechnology
-
Drug Discovery Tools
- Genomics-Proteomics
-
Drug Discovery Tools
Deal Status
- Final
Deal Type
-
Financing
- FOPO
Already a Biomedtracker subscriber?
You have access to the full deal record through your subscription
Want to become a subscriber?
Subscribers get more deal details, updates, deal financials and deal products.
Questions?
Questions?
Please contact Sales at: (212) 520-2765 or email [email protected]
Related Companies
You must sign in to use this functionality
Authentication.SignIn.HeadSignInHeader
Agios nets $516mm through public offering
Email Deal
All set! This article has been sent to my@email.address.
All fields are required. For multiple recipients, separate email addresses with a semicolon.
DCD.EmailPopout.Notice